Pain News and Research

Latest Pain News and Research

AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to treat PBA

AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).

10 Feb 2010

Top ten myths about sex

Boston Medical Group, a national physician network specializing in the treatment of erectile dysfunction and premature ejaculation, today released ten of the top myths surrounding sex. From which gender spends the most time fantasizing to whether size really matters, the list covers some of the common misconceptions about time spent between the sheets.

10 Feb 2010

YM BioSciences receives additional AeroLEF patents in U.S.

YM BioSciences Inc., announced that it has been granted two additional patents in the US for AeroLEF(R), the Company's proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe acute pain. US patent numbers 7,648,981 and 7,648,982 extend the life of YM's AeroLEF patent estate in the US to 2024.

10 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.

10 Feb 2010

ONA warns nursing cuts may result in longer wait times for cancer patients

The Ontario Nurses' Association (ONA) is warning that London-area cancer patients will face longer wait times as London Health Sciences Centre cuts five of its 22 full-time and four of its part-time front-line primary care nurses providing outpatient cancer program care.

10 Feb 2010

Patients treated with Biodesign Inguinal Hernia Graft experience less postoperative pain

Results from a clinical study led by Luca Ansaloni, M.D., showed that Cook Medical’s Biodesign Inguinal Hernia Graft causes less postoperative pain and discomfort while creating a repair as durable as synthetic mesh when used in Lichtenstein’s hernioplasty procedures.

10 Feb 2010

Pivotal Research to study investigational drug for menstrual cramps

A leading clinical research center in Peoria has joined an international research program to study an investigational drug designed as a possible treatment for painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States.

10 Feb 2010

New research suggests closantel drug may be useful in combating river blindness

Scientists at The Scripps Research Institute have discovered a potential new use for the drug closantel, currently the standard treatment for sheep and cattle infected with liver fluke. The new research suggests that the drug may be useful in combating river blindness, a tropical disease that is the world's second leading infectious cause of blindness for humans.

10 Feb 2010

Glide Pharma to utilize $4.3M funding for progressing octreotide programme into clinical development

Glide Pharma, a specialty pharmaceutical company focused on the needle-free administration of solid dose therapeutics and vaccines, today announced that it has completed an oversubscribed GBP2.7 million ($4.3 million) investment round. The fundraising was supported by a number of existing institutional and private investors, including Hygea VCT and Oxford Technology VCTs. The company has now completed four successful investment rounds, securing funding totalling approximately GBP10 million.

10 Feb 2010

Toronto Rehab scientists develop SoleSensor to help older people stay on their feet

In an aging society, falling is a growing problem. Just one bad fall can mark the start of a downward spiral in an older person's health and quality of life. The cost of treating falls also puts a heavy burden on the health care system. Toronto Rehab scientists have developed a simple footwear insole called SoleSensor(TM), which has proven to improve balance and prevent falls.

10 Feb 2010

Breast enhancement surgery: Pros, cons and options

With ever growing cases of breast enlargement surgery in the UK, CosmeticSurgeryGuru can report that patients interested in undergoing breast enhancement surgery in 2010 continue to make the choice between saline and silicone implants. CosmeticSurgeyGuru notes that in 2009 breast enhancements remained the most popular procedure for women in the UK.

10 Feb 2010

Racial gaps persist in women's heart-health awareness

Racial gaps exist in women's heart-health awareness, women's knowledge of heart attack warning signs requires attention and nearly half of women report they would not call 9-1-1 if they were having heart attack symptoms, according to new research published in Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association.

10 Feb 2010

Laser Spine Institute recognized as ‘Medical Partner of the Year’

This year, Gridiron Greats recognized LSI at the event as Medical Partner of the Year. LSI's medical director Dr. Michael Perry and CEO Bill Horne accepted the award.

10 Feb 2010

Hospitals use new robotic catheter guidance system to treat abnormal heart rhythms

The robotic system "enhances a doctor's natural ability, and we believe it will contribute to improved procedural outcomes," said Dr. David Wilber of Loyola University Health System, a nationally known researcher in heart rhythm disorders.

10 Feb 2010

Children with depressive symptoms may have greater affinity for sweets, says study

New research from the Monell Center reports that children's response to intense sweet taste is related to both a family history of alcoholism and the child's own self-reports of depression.

10 Feb 2010

Research opens door for advancement of new category of painkillers

Research led by a scientist at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has opened the door for the advancement of a new category of painkillers, called TRPV1 antagonists.

10 Feb 2010

Acupuncture: An effective pain management therapy for pediatric patients

Doctors at Rush University Medical Center are offering pediatric patients diagnosed with chronic illnesses acupuncture therapy to help ease the pain and negative side effects like nausea, fatigue, and vomiting caused by chronic health conditions and intensive treatments.

10 Feb 2010

TI commences Phase IIa clinical trial for its lead molecule in CDH

Trigemina, Inc. (TI), a Mountain View based startup, has begun a Phase IIa clinical trial for its lead molecule in Chronic Daily Headache (CDH) in collaboration with Dr. Egilius Spierings at MedVadis Research Corporation located outside of Boston.

10 Feb 2010